Skip to main content
Top
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Association of XRCC5 VNTR polymorphism with the development of chronic myeloid leukemia

Authors: Manjula Gorre, Prajitha Edathara Mohandas, Sailaja Kagita, Sandhya Annamaneni, Raghunadharao Digumarti, Vishnupriya Satti

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Double-strand breaks (DSBs) inducing agents influence the fidelity of DNA repair in both normal cells and leukemic cells, causing major genomic instability. In eukaryotic cells, non-homologous end joining pathway (NHEJ) is the major mechanism for DSB repair. Human X-ray repair cross-complementing 5 (XRCC5) gene encodes for the protein KU86, an important component of NHEJ pathway. Variable number of tandem repeats (VNTR) polymorphism (rs 6147172) in the promoter region of XRCC5 gene was shown to have effect on gene expression and was found to be associated with the development of several cancers. We analyzed VNTR polymorphism of XRCC5 gene in 461 chronic myeloid leukemia (CML) cases and 408 controls by polymerase chain reaction. Our results showed that frequency of 0R/0R genotype was significantly elevated in CML cases compared to that of controls (p = 0.05). Significant difference in the genotype distribution was observed between cases and controls (p = 0.02). The risk of CML development was found to be elevated for individuals carrying lower repeats (1R p = 0.03; 0R p = 0.007). Elevated 0R/0R genotype frequency was found to be significantly associated with early age at onset (≤30 years) and slightly elevated in chronic phase and poor hematologic response to imatinib mesylate. The influence of zero repeat on enhanced expression of XRCC5 might confer risk to error-prone repair leading to genomic instability and CML. Hence, the VNTR polymorphism in the promoter region of XRCC5 gene could serve as an important prognostic marker in CML development.
Literature
1.
go back to reference Faderl S, Talpaz M, Estrov Z, OBrien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72.PubMedCrossRef Faderl S, Talpaz M, Estrov Z, OBrien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72.PubMedCrossRef
2.
go back to reference Khanna KK, Jackson SP. DNA double strand breaks: signaling, repair, and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRef Khanna KK, Jackson SP. DNA double strand breaks: signaling, repair, and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRef
3.
go back to reference Nicola B, Terry JG, Manyee C, Ghulam JM, Feyruz VR. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key non homologous end-joining proteins. Cancer Res. 2003;63:1798–805. Nicola B, Terry JG, Manyee C, Ghulam JM, Feyruz VR. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key non homologous end-joining proteins. Cancer Res. 2003;63:1798–805.
4.
go back to reference Cai QQ, Plet A, Imbert J, Lafage-Pochitaloff M, Cerdan C, Blanchard JM. Chromosomal location and expression of the genes coding for Ku p70 and p80 in human cell lines and normal tissues. Cytogenet Cell Genet. 1994;65:221–7.PubMedCrossRef Cai QQ, Plet A, Imbert J, Lafage-Pochitaloff M, Cerdan C, Blanchard JM. Chromosomal location and expression of the genes coding for Ku p70 and p80 in human cell lines and normal tissues. Cytogenet Cell Genet. 1994;65:221–7.PubMedCrossRef
5.
go back to reference Stronati L, Gensabella G, Lamberti C, Barattini P, Frasca D, Tanzarella C, et al. Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. Cancer. 2001;92:2484–92.PubMedCrossRef Stronati L, Gensabella G, Lamberti C, Barattini P, Frasca D, Tanzarella C, et al. Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. Cancer. 2001;92:2484–92.PubMedCrossRef
6.
go back to reference Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, et al. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene. 2001;20:739–47.PubMedCrossRef Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, et al. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene. 2001;20:739–47.PubMedCrossRef
7.
go back to reference Yang MD, Tsai CW, Chang WS, Tsou YA, Wu CN, Bau DT. Predictive role of XRCC5/XRCC6 genotypes in digestive system cancers. World J Gastrointest Oncol. 2011;3(12):175–81.PubMedCentralPubMedCrossRef Yang MD, Tsai CW, Chang WS, Tsou YA, Wu CN, Bau DT. Predictive role of XRCC5/XRCC6 genotypes in digestive system cancers. World J Gastrointest Oncol. 2011;3(12):175–81.PubMedCentralPubMedCrossRef
8.
go back to reference Ludwig DL, Chen F, Peterson SR, Nussenzweig A, Li GC, Chen DJ. Ku80 gene expression is Sp1-dependent and sensitive to CpG methylation within a novel cis element. Gene. 1997;199:181–94.PubMedCrossRef Ludwig DL, Chen F, Peterson SR, Nussenzweig A, Li GC, Chen DJ. Ku80 gene expression is Sp1-dependent and sensitive to CpG methylation within a novel cis element. Gene. 1997;199:181–94.PubMedCrossRef
9.
go back to reference Wang S, Wang M, Yin S, Fu G, Li C, Chen R, et al. A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat Res. 2008;638:26–36.PubMedCrossRef Wang S, Wang M, Yin S, Fu G, Li C, Chen R, et al. A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat Res. 2008;638:26–36.PubMedCrossRef
10.
go back to reference Rajaei M, Saadat I, Saadat M. High-resolution melting analysis for detection of variable number of tandem repeats polymorphism of XRCC5. Biochem Biophys Res Commun. 2012;425:398–400.PubMedCrossRef Rajaei M, Saadat I, Saadat M. High-resolution melting analysis for detection of variable number of tandem repeats polymorphism of XRCC5. Biochem Biophys Res Commun. 2012;425:398–400.PubMedCrossRef
11.
go back to reference Rajaei M, Saadat I, Saadat I. The novel allele (3R) of the VNTR polymorphism in the XRCC5promoter region dramatically decreases the gene expression. Biochem Biophys Res Commun. 2013;430:640–1.PubMedCrossRef Rajaei M, Saadat I, Saadat I. The novel allele (3R) of the VNTR polymorphism in the XRCC5promoter region dramatically decreases the gene expression. Biochem Biophys Res Commun. 2013;430:640–1.PubMedCrossRef
12.
go back to reference Rajaei M, Saadat I, Saadat M. Introducing a novel allele for the polymorphism of variable number of tandem repeats in the promoter region of XRCC5. Biochem Biophys Res Commun. 2012;427:503–5.PubMedCrossRef Rajaei M, Saadat I, Saadat M. Introducing a novel allele for the polymorphism of variable number of tandem repeats in the promoter region of XRCC5. Biochem Biophys Res Commun. 2012;427:503–5.PubMedCrossRef
13.
go back to reference Lahiri DK, Nurnberger Jr JI. A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19(19):5444.PubMedCentralPubMedCrossRef Lahiri DK, Nurnberger Jr JI. A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19(19):5444.PubMedCentralPubMedCrossRef
14.
go back to reference Wang G, Wang S, Shen Q, Yin S, Li C, Li A, et al. Polymorphisms inXRCC5, XRCC6, XRCC7 genes are involved in DNA double-strand breaks (DSBs) repair associated with the risk of acute myeloid leukemia (AML) in Chinese population. J Nanjing Med Univ. 2009;23(2):93–9.CrossRef Wang G, Wang S, Shen Q, Yin S, Li C, Li A, et al. Polymorphisms inXRCC5, XRCC6, XRCC7 genes are involved in DNA double-strand breaks (DSBs) repair associated with the risk of acute myeloid leukemia (AML) in Chinese population. J Nanjing Med Univ. 2009;23(2):93–9.CrossRef
Metadata
Title
Association of XRCC5 VNTR polymorphism with the development of chronic myeloid leukemia
Authors
Manjula Gorre
Prajitha Edathara Mohandas
Sailaja Kagita
Sandhya Annamaneni
Raghunadharao Digumarti
Vishnupriya Satti
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1120-5

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine